Novel TROP2 Biomarker Predicts Outcomes for Datopotamab Deruxtecan in NSCLC: TROPION-Lung01 Phase III

An exploratory analysis of the TROPION-Lung01 Phase III trial found that the TROP2 biomarker, assessed via AstraZeneca’s computational pathology platform, Quantitative Continuous Scoring (QCS), effectively predicted clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated…

Read MoreNovel TROP2 Biomarker Predicts Outcomes for Datopotamab Deruxtecan in NSCLC: TROPION-Lung01 Phase III

Phase 3 CAMZYOS® (mavacamten) Study Confirms Efficacy and Safety for Obstructive Hypertrophic Cardiomyopathy

Bristol Myers Squibb (NYSE: BMY) has announced new long-term follow-up data from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study. This data evaluates the efficacy and safety of CAMZYOS® (mavacamten) in adults with New York Heart Association (NYHA) class…

Read MorePhase 3 CAMZYOS® (mavacamten) Study Confirms Efficacy and Safety for Obstructive Hypertrophic Cardiomyopathy

Sensorion to Lead Hearing Loss Symposium at World Congress of Audiology 2024 in Paris

Sensorion (FR0012596468 – ALSEN), a leading clinical-stage biotechnology company focused on innovative therapies for hearing loss, has announced its participation in the 36th World Congress of Audiology (WCA) in Paris from September 19-22, 2024. The company will host a symposium…

Read MoreSensorion to Lead Hearing Loss Symposium at World Congress of Audiology 2024 in Paris

EDX Medical Partners with Caris Life Sciences for Molecular Profiling Distribution in UK and Nordic Countries

EDX Medical Group plc, a company focused on innovative digital diagnostics for personalized treatment in cancer, heart disease, and infectious diseases, has signed a distribution agreement with Caris Life Sciences®. Caris, a U.S.-based leader in next-generation AI TechBio and precision…

Read MoreEDX Medical Partners with Caris Life Sciences for Molecular Profiling Distribution in UK and Nordic Countries

ESC 2024: INFINITY-SWEDEHEART Trial Confirms DynamX Bioadaptor Success

Elixir Medical, a developer of innovative cardiovascular technologies, announced that the INFINITY-SWEDEHEART Randomized Controlled Trial (RCT) has met its primary endpoint. The trial compared the novel DynamX® Coronary Bioadaptor System with the Resolute Onyx™ zotarolimus drug-eluting stent (DES), showing non-inferiority…

Read MoreESC 2024: INFINITY-SWEDEHEART Trial Confirms DynamX Bioadaptor Success

UnitedHealthcare Grants $114,500 to Seven Iowa Organizations for Social Drivers of Health

UnitedHealthcare has awarded $114,500 to seven Iowa organizations to enhance health outcomes by addressing social determinants of health. This funding aligns with UnitedHealthcare’s goal to positively impact underserved communities and improve access to essential resources. Marsha Connor, CEO of UnitedHealthcare…

Read MoreUnitedHealthcare Grants $114,500 to Seven Iowa Organizations for Social Drivers of Health

Collaborative Bridges Selects HealthEC for Behavioral Health Care Coordination

Collaborative Bridges, a network of West Side Chicago safety net hospitals and mental health agencies, has selected HealthEC’s data and analytics solution to enhance care coordination for behavioral health patients. HealthEC’s technology will integrate Electronic Health Records and workflows, ensuring…

Read MoreCollaborative Bridges Selects HealthEC for Behavioral Health Care Coordination